scholarly journals Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells

2020 ◽  
Vol 11 (1) ◽  
pp. 25-40 ◽  
Author(s):  
Yangwei Fan ◽  
Ke Ma ◽  
Jiayu Jing ◽  
Chuying Wang ◽  
Yuan Hu ◽  
...  
2020 ◽  
Vol 99 (6) ◽  
pp. 151096 ◽  
Author(s):  
Macarena Guereño ◽  
Magali Delgado Pastore ◽  
Ana Clara Lugones ◽  
Magalí Cercato ◽  
Laura Todaro ◽  
...  

2009 ◽  
Vol 30 (12) ◽  
pp. 1648-1658 ◽  
Author(s):  
Qian-mei Zhou ◽  
Song Wang ◽  
Hui Zhang ◽  
Yi-yu Lu ◽  
Xiu-feng Wang ◽  
...  

2013 ◽  
Vol 43 (6) ◽  
pp. 1935-1942 ◽  
Author(s):  
QIAN-QIAN GENG ◽  
DAN-FENG DONG ◽  
NAN-ZHENG CHEN ◽  
YIN-YING WU ◽  
EN-XIAO LI ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1468
Author(s):  
Sumeyye Cavdarli ◽  
Larissa Schröter ◽  
Malena Albers ◽  
Anna-Maria Baumann ◽  
Dorothée Vicogne ◽  
...  

The O-acetylated form of GD2, almost exclusively expressed in cancerous tissues, is considered to be a promising therapeutic target for neuroectoderm-derived tumors, especially for breast cancer. Our recent data have shown that 9-O-acetylated GD2 (9-OAcGD2) is the major O-acetylated ganglioside species in breast cancer cells. In 2015, Baumann et al. proposed that Cas 1 domain containing 1 (CASD1), which is the only known human sialyl-O-acetyltransferase, plays a role in GD3 O-acetylation. However, the mechanisms of ganglioside O-acetylation remain poorly understood. The aim of this study was to determine the involvement of CASD1 in GD2 O-acetylation in breast cancer. The role of CASD1 in OAcGD2 synthesis was first demonstrated using wild type CHO and CHOΔCasd1 cells as cellular models. Overexpression using plasmid transfection and siRNA strategies was used to modulate CASD1 expression in SUM159PT breast cancer cell line. Our results showed that OAcGD2 expression was reduced in SUM159PT that was transiently depleted for CASD1 expression. Additionally, OAcGD2 expression was increased in SUM159PT cells transiently overexpressing CASD1. The modulation of CASD1 expression using transient transfection strategies provided interesting insights into the role of CASD1 in OAcGD2 and OAcGD3 biosynthesis, and it highlights the importance of further studies on O-acetylation mechanisms.


Lab on a Chip ◽  
2021 ◽  
Vol 21 (4) ◽  
pp. 746-754
Author(s):  
Menglin Shang ◽  
Su Bin Lim ◽  
Kuan Jiang ◽  
Yoon Sim Yap ◽  
Bee Luan Khoo ◽  
...  

Microfluidic studies of hydrostatic pressure-enhanced doxorubicin resistance in human breast cancer cells.


Neoplasia ◽  
2018 ◽  
Vol 20 (8) ◽  
pp. 857-870 ◽  
Author(s):  
Federica Alessandrini ◽  
Laura Pezzè ◽  
Daniel Menendez ◽  
Michael A. Resnick ◽  
Yari Ciribilli

2021 ◽  
Vol 22 (15) ◽  
pp. 8165
Author(s):  
Amanda Chantziou ◽  
Kostas Theodorakis ◽  
Hara Polioudaki ◽  
Eelco de Bree ◽  
Marilena Kampa ◽  
...  

In breast cancer, expression of Cluster of Differentiation 24 (CD24), a small GPI-anchored glycoprotein at the cell periphery, is associated with metastasis and immune escape, while its absence is associated with tumor-initiating capacity. Since the mechanism of CD24 sorting is unknown, we investigated the role of glycosylation in the subcellular localization of CD24. Expression and localization of wild type N36- and/or N52-mutated CD24 were analyzed using immunofluorescence in luminal (MCF-7) and basal B (MDA-MB-231 and Hs578T) breast cancer cells lines, as well as HEK293T cells. Endogenous and exogenously expressed wild type and mutated CD24 were found localized at the plasma membrane and the cytoplasm, but not the nucleoplasm. The cell lines showed different kinetics for the sorting of CD24 through the secretory/endocytic pathway. N-glycosylation, especially at N52, and its processing in the Golgi were critical for the sorting and expression of CD24 at the plasma membrane of HEK293T and basal B type cells, but not of MCF-7 cells. In conclusion, our study highlights the contribution of N-glycosylation for the subcellular localization of CD24. Aberrant N-glycosylation at N52 of CD24 could account for the lack of CD24 expression at the cell surface of basal B breast cancer cells.


Sign in / Sign up

Export Citation Format

Share Document